期刊文献+

注射用替加环素临床用药分析 被引量:4

Analysis of Clinical Application of Tigecycline in a Hospital
下载PDF
导出
摘要 目的:回顾性分析替加环素在胸科医院患者中的使用情况,以期为抗感染合理用药提供理论依据。方法:抽取2016年1月~2018年1月应用替加环素的52例住院患者病历,从管理指标、用药指征、用药过程和用药结果等方面分析替加环素临床合理用药及超说明书用药情况。结果:在使用替加环素的患者中,主要集中于重症监护病房(ICU),用药原因主要是肺部感染。有会诊记录的比例达88.46%(目标值100%);符合超说明书用药标准率为84.62%(目标值90%),其中主要为超适应症、超剂量用药。48例(92.31%)作了病原学检查,84.62%有药敏试验结果。52例患者药物利用指数(DUI)值为1.082。结论:替加环素临床治疗总有效率为59.62%,超说明书用药现象比较普遍。 Objective:The use of tigecycline on inpatients was retrospectively analyzed in a chest hospital in order to provide a theoretical basis for rational use of anti-infective drugs.Methods:The medical records of 52 inpatients who received tigecycline from January 2016 to January 2018 were statistically analyzed from the aspects of management indicators and medicinal indications,procedures and results;meanwhile the off-label drug use was also studied.Results:Among the patients who used tigecycline,the medication was mainly applied in the intensive care unit(ICU)and the main cause was pulmonary infections.The proportion of cases with consultation records was 88.46%(target value 100%);the standard rate of use in the indications was 84.62%(target value 90%),of which the off-label use was mainly for hyper-indication and over-dosage.Pathogen examinations were done for 48 patients(92.31%),and 84.62%had susceptibility test results.The drug utilization index(DUI)was 1.082 in the 52 patients.Conclusion:The clinical effective rate of tigecycline was 59.62%and the off-label use was common.
作者 鲁涛 周秋云 王洁 丁红梓 LU Tao;ZHOU Qiuyun;WANG Jie;DING Hongzi(Department of Pharmacy,Nanjing Chest Hospital Affiliated to Medical College of Southeast University,Nanjing 210029,China)
出处 《药学与临床研究》 2019年第6期467-470,共4页 Pharmaceutical and Clinical Research
基金 南京市医学科技发展一般项目(YKK17184)
关键词 替加环素 药物利用评价 合理用药 负荷剂量 药品不良反应 耐药性 Tigecycline Drug utilization evaluation Rational drug use Loading dose Adverse drug reactions Drug resistance
  • 相关文献

参考文献11

二级参考文献92

  • 1Olson MW, Ruzin A, Feyfant E, et al. Functional, biophysical, and structural bases for antibacterial activity oftigecycline.[J].Antimicrobial Agents and Chemotherapy, 2006, 6:2156-2166.
  • 2Gemmell CG, Edwards DI, Fraise AP, et al. Warren Guidelinesfor the prophylaxis and treatment of methicillin2resistan t Staphylococcus aureus (MRSA) infections in the UK[J]. Antimicrobial Chemotherapy, 2006,57:589-608.
  • 3Curcio J. Treatment of recurrent urosepsis with tigecycline: A pharmacological perspective[J]. J ClinMicrobiol 2008,46:1892- 1893.
  • 4Zhanel GG, Homenuik K, Nichol K, et al. The review with the teWacyclines[J]. Drugs, 2004, 64:63-88.
  • 5Projan SJ. Preclinicalpharmacology of GAR-936, a novel glycylcycline antibacterial agent[J]. Pharmacotherapy, 2000,20:219S-228 S.
  • 6Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent[J]. Am J Heal thSystPharm, 2006, 63 (13) : 1235-1243.
  • 7Pankey GA. Tigecycline[J]. J AntimicrobChem other, 2005, 56(3): 470-480.
  • 8Bauer G, Berens C, Projan S J, et al. Comparison of tetracyclineand tigecycline binding to ribosomesmapped by dimethylsulphateand drug2directed Fe2+ cleavage of 16S rRNA[J]. J AntimicrobChem other, 2004, 53 (4) : 592-599.
  • 9Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of tigecycline[J]. Clin lnfectDis, 2005, 41 (SupplS) : S333-S340.
  • 10Wyeth Pharmaceutics. Tygacil(Tigecycline) for Injection [packageinsert] [M]. Philadelphia, PA:Wyeth Pharmaceuticals Inc, 2005.

共引文献578

同被引文献31

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部